Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EPFL launches Protein Expression Core Facility

28.07.2006
EPFL is adding an exciting new dimension to the life science research capabilities in the Lake Geneva area and around Switzerland with the launching of a Protein Expression Core Facility. This facility, founded and directed by Professor Florian Wurm and located in EPFL’s Laboratory of Cellular Biotechnology, will provide recombinant proteins efficiently and at minimal cost to scientists doing basic research both within and outside Switzerland.

Producing proteins is a time-consuming, painstaking process, particularly from mammalian cell lines, and the investment required in terms of time, expertise, cost and infrastructure prevents most researchers from taking on the task in their own laboratories. Obtaining proteins from commercial sources is prohibitively expensive for scientists on tight budgets.

“Having this service close at hand has been fantastic for my research,” says EPFL researcher Patrick Fraering. “In my field [neurodegenerative disease] developments move very quickly. In order to stay competitive internationally, I need quick access to proteins from mammalian cell lines, and there is no way I could produce them with this level of efficiency myself.”

Building on the demonstrated benefits of the facility to EPFL researchers, the School of Life Sciences decided to formalize the facility and extend the service to scientists doing basic research outside EPFL. This will allow the Facility to recoup some costs and has the added benefit of stimulating collaborations and cross-institutional exchange. It’s cost-effective for users, because even though they will be charged a fee for the proteins, it’s far below what they would pay for commercial proteins and roughly a quarter of what it would cost them to produce the proteins themselves. And with a tight turnaround time – the facility can produce proteins from mammalian cells in less than four weeks – researchers can quickly follow up on promising leads. Once the development of a protein reaches a clinical or commercial stage, production will be transferred to a commercial facility.

The facility also provides training in gene transfer techniques and cultivation of cells in suspension. As facility manager David Hacker points out, “by offering guidance and training, we can enhance the chance that researchers’ projects will succeed.”

Recombinant proteins - From a Swiss past to a Swiss future?

In 1978, Swiss scientist Werner Arber shared the Nobel prize in medicine with Americans Daniel Nathans and Hamilton Smith for discovering a technique to incorporate non-native DNA into living cells. The re-combined, or “recombinant”, DNA holds instructions for the cell to produce the non-native protein which can subsequently be extracted and purified.

The 25,000 genes that make up human genome hold the blueprints for the manufacture of anywhere from 250,000 - 1 million proteins. But only about 50 of these proteins are understood well enough to be used in therapeutic applications. Insulin, EPO, and herceptin, an antibody used in breast cancer treatment, are a few better-known examples.

The global market for antibodies, proteins, and hormones produced using the recombinant DNA technique is currently on the order of $20 billion. Global demand for insulin is expected to rise by 14% annually. Most biomedical researchers agree that the therapeutic and market potential of recombinant proteins is not even close to being fully exploited. “It’s very important that we take advantage of the opportunities available in recombinant proteins,” notes Wurm. “A lack of opportunity for exploring this potential will diminish the European contribution to biomedical research considerably, and we’re likely to get left behind in the market as well.”

“If we want to jump-start biomedical research on proteins in Europe, the path from idea to innovation needs to be optimized,” urges Wurm. “With this facility, EPFL is in a key position to help make this happen.”

Mary Parlange | alfa
Further information:
http://actualites.epfl.ch/presseinfo-com?id=370

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>